Our results, shown in Fig. 9a-b, demonstrated that classifiers incorporating factors such as FAB, age, FANCI, FAAP100 expression, and others contribute to cytogenetic risk classification in AML patients. This evidence concerns the gene FAAP100 and acute myeloid leukemia.